Product Description
STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. (Sourced from: https://www.sutrobio.com/sutro-biopharma-presents-data-from-ongoing-phase-1-dose-escalation-study-for-stro-001-for-the-treatment-of-b-cell-non-hodgkin-lymphoma-at-the-62nd-american-society-of-hematology-annual-meeting/)
Mechanisms of Action: CD74 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sutro Biopharma, Inc.
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle-Cell Lymphoma|Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03424603 |
STRO-001-BCM1 | P1 |
Completed |
Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma |
2024-02-15 |
2024-06-12 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/30/2023 |
News Article |
Sutro Biopharma to Participate in Upcoming Investor Conferences |
|
06/26/2023 |
News Article |
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration |
|
06/26/2023 |
News Article |
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration |
|
06/03/2023 |
News Article |
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 |